GW501516 – (317318-70-0)

GW501516 is a PPARδ receptor agonist developed in the 1990s through a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline. Initially investigated for its potential in treating metabolic and cardiovascular diseases, the drug was discontinued in 2007 after animal studies revealed it caused rapid cancer development in multiple organs.

Its mechanism of action involves activating PPARδ, which enhances fatty acid metabolism and energy expenditure, but it also poses significant cancer risks at higher doses.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

GW501516 is a PPARδ receptor agonist developed in the 1990s through a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline. Initially investigated for its potential in treating metabolic and cardiovascular diseases, the drug was discontinued in 2007 after animal studies revealed it caused rapid cancer development in multiple organs.

Its mechanism of action involves activating PPARδ, which enhances fatty acid metabolism and energy expenditure, but it also poses significant cancer risks at higher doses.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/GW501516
https://www.medchemexpress.com/GW-501516.html
https://www.medkoo.com/products/7473
https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/gw501516

Other Names	Endurobol, GW 501516, GW-501516
IUPAC Name	2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1, 3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid
CAS	317318-70-0
Molecular Weight	453.5
Molecular Formula	C21H18F3NO3S2
SMILES	CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=CC=C(C=C3)C(F)(F)F)C)OCC(=O)O

Products

Consulting & Services

Check Out Our Research And Updates

GW501516 – (317318-70-0)

Its mechanism of action involves activating PPARδ, which enhances fatty acid metabolism and energy expenditure, but it also poses significant cancer risks at higher doses.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/GW501516
https://www.medchemexpress.com/GW-501516.html
https://www.medkoo.com/products/7473
https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/gw501516

About Us

Products

Services

Quick Contact

Check Out Our Research And Updates

GW501516 – (317318-70-0)

Its mechanism of action involves activating PPARδ, which enhances fatty acid metabolism and energy expenditure, but it also poses significant cancer risks at higher doses.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/GW501516 https://www.medchemexpress.com/GW-501516.html https://www.medkoo.com/products/7473 https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/gw501516

Related products

Quick Contact

https://en.wikipedia.org/wiki/GW501516
https://www.medchemexpress.com/GW-501516.html
https://www.medkoo.com/products/7473
https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/gw501516